KONEXFood & Beverage178600

Daedong Korea Ginseng

₩1,880▲ 10.65%2026-10-02 close

Market Cap

₩8.4B

Turnover

₩1,880

Volume

1 shares

Shares out.

4.5M

PER

—

PBR

—

EPS

—

Dividend Yield

0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Red Ginseng Maturity Squeezes Profitability

Daedong Korea Ginseng, a domestic red ginseng specialist, faces a structural profitability squeeze as the Korean health functional food market matures, with brand enhancement and overseas export expansion emerging as the pivotal variables for medium-term recovery.

1
FY2024 (June fiscal year-end) operating profit collapsed 53.2% and net profit fell 81.4%, signaling severe profitability deterioration
2
Manufactures whole red ginseng root, soft capsules, and red ginseng candy under the 'Bullogeon' brand; holds export footholds in Hong Kong, the US, and the UK
3
Domestic health functional food market reached approximately KRW 5.96 trillion in 2025 (+0.2%), while the red ginseng ingredient sub-market recovered modestly to KRW 953.6 billion
4
Reference-date trading value of just KRW 2,080 (equivalent to a single share) underscores the near-total illiquidity inherent to the KONEX listing
5
Global repositioning of red ginseng into anti-aging, blood glucose management, and brain health applications creates niche opportunities for specialized smaller producers

Business structure

Daedong Korea Ginseng is a specialized red ginseng manufacturer and processor, using Korean ginseng as its primary raw material to produce whole red ginseng root and related processed products.

The proprietary 'Bullogeon' brand—centered on immunity enhancement and fatigue recovery—anchors the product lineup under the management slogan of 'superior quality, global reach, and product accessibility.' The core product range is built around whole processed red ginseng root, with selected formats such as red ginseng candy and soft capsules sourced through external manufacturing partners to broaden the portfolio.

On the export front, the company has an established presence in Hong Kong, the United States, and the United Kingdom, providing an initial commercial foundation for further overseas channel diversification.

Academically, Daedong maintains a collaborative relationship with the Ginseng Industry Research Center at Chung-Ang University, supporting product efficacy research and raw material quality control.

The company also holds recommended-vendor status from the Korea Oriental Medicine Association, which facilitates access to professional distribution channels such as oriental pharmacies and clinics. The competitive landscape is dominated by KGC Ginseng Corp.

(Jung Kwan Jang), which commands overwhelming brand recognition, followed by NongHyup Hongsam and Huons-N as mid-tier rivals. Daedong is at a clear disadvantage in scale and marketing resources relative to these incumbents, yet it seeks to occupy specialized manufacturing niches and targeted distribution segments.

Given that online malls now account for approximately 71% of health functional food distribution, digital channel competitiveness has become the decisive variable separating smaller manufacturers from scale-advantaged peers.

Recent trends

Daedong Korea Ginseng's most recently disclosed financial results reflect a broadly deteriorating performance trajectory.

Based on FnGuide public data for the fiscal year ending June 2024 (IFRS non-consolidated), revenues declined 4.7% year-on-year while operating profit collapsed 53.2% and net profit fell 81.4%, marking a pronounced erosion of profitability.

Publicly available information indicates annual revenues of approximately KRW 45.7 billion, confirming the company's positioning as a small-scale operator.

The sharp decline in profitability likely reflects a combination of higher raw material procurement costs for ginseng inputs, intensifying pricing pressure within the red ginseng market, and the adverse amplification effect of operating leverage on fixed costs when volumes contract.

As of the reference date (June 7, 2026), the share price stood at KRW 2,080, up 4.26% from the prior session, yet still approximately 39% below the 52-week high of KRW 3,415. Conversely, the current price represents roughly a 21% recovery from the 52-week low of KRW 1,721, suggesting a modest rebound from the trough.

Critically, the reference-date trading value of just KRW 2,080—equivalent to a single share—indicates virtually no price discovery is occurring, while KONEX-wide daily average trading volumes have been on a consistent multi-year declining trend, leaving the structural liquidity deficit unresolved.

Outlook

In the near term, the most critical question is whether the company can reverse its sharp profitability decline.

The red ginseng ingredient market's modest recovery to approximately KRW 953.6 billion in 2025 is a constructive signal, but with the overall health functional food market stagnating near KRW 5.96 trillion and spending concentrating increasingly among top-tier brands, maintaining pricing power and market share remains challenging for smaller operators.

Over the medium to long term, overseas export expansion stands out as the most compelling growth driver.

The accelerating global repositioning of red ginseng into anti-aging, blood glucose management, and brain health applications—backed by growing clinical evidence—suggests that product upgrades aligned with these demand vectors could unlock meaningful new export revenue.

The record health functional food purchase experience rate of 83.6% and the broadening of consumption across all demographic cohorts provide a structurally supportive demand backdrop.

However, the structural liquidity deterioration of the KONEX market and diminishing expectations for an uplist to KOSDAQ will likely continue to cap meaningful stock price re-rating.

Overall, a period of elevated uncertainty is expected to persist until tangible evidence of earnings recovery and concrete overseas channel development becomes visible.

Bull factors

Global Functional Repositioning of Red Ginseng Unlocks Export Upside

There is a clear global trend repositioning red ginseng beyond traditional immunity and fatigue applications toward anti-aging, blood glucose control, and brain health.

Clinical evidence is accumulating, including a 2024 domestic study showing that red ginseng extract powder contributed to improvements in fasting and postprandial blood glucose levels in pre-diabetic adults.

Daedong's established export presence in Hong Kong, the US, and the UK provides an existing channel infrastructure that could amplify revenue if differentiated, functionally advanced products are developed.

The ongoing academic collaboration with Chung-Ang University's Ginseng Industry Research Center is a constructive support for building this functional product development capability.

Record Health Food Purchase Penetration Broadens Demand Base

According to the Korea Health Functional Food Association, the domestic health functional food purchase experience rate reached a five-year high of 83.6% in 2025, with senior household purchase rates rising 2.6 percentage points year-on-year, reflecting consumption spreading across all demographic cohorts.

The broader shift from family-unit purchasing to individualized daily health routines may benefit smaller manufacturers capable of offering personalized product formats with agility that larger companies may lack.

Red ginseng's sustained position among the top five functional ingredients—alongside probiotics and multivitamins—also underpins a stable baseline consumer demand that supports the sector's long-term viability.

Professional Credibility Backed by Academia and Industry Endorsement

Daedong Korea Ginseng's recommended-vendor status from the Korea Oriental Medicine Association affords relatively favorable access to professional distribution channels such as oriental pharmacies and traditional medicine clinics.

Its academic collaboration with Chung-Ang University's Ginseng Industry Research Center provides scientific credibility in raw material quality control and product efficacy research, serving as a meaningful brand differentiation asset.

The company's identity as a specialized small-scale manufacturer can also support a credible 'authentic red ginseng producer' positioning that differentiates it from large-scale OEM and distribution-driven competitors.

Bear factors

Profitability Structure Vulnerability Exposed by Earnings Collapse

The 53.2% plunge in operating profit and 81.4% decline in net profit in FY2024 (June fiscal year-end) points to structural vulnerabilities in cost structure and operating leverage, beyond a merely cyclical earnings setback.

The outsized profit decline relative to the comparatively modest revenue contraction of 4.7% suggests a compounding effect from rising raw material costs and the adverse impact of fixed-cost operating leverage.

Achieving a meaningful profitability recovery requires simultaneous improvements across revenue, cost of goods sold, and operational efficiency—a combination that is particularly difficult to execute quickly given the constraints of a small-scale manufacturing structure.

Intensifying Top-Tier Brand Concentration Structurally Disadvantages Small Players

KGC Ginseng Corp. (Jung Kwan Jang) commands an overwhelming first-recall brand recognition of 34.9% in the domestic health functional food market, followed by Chong Kun Dang Health at 19.7%—a gap that smaller producers face extreme difficulty closing.

As the overall market enters a prolonged stagnation phase, spending is concentrating increasingly among top-tier brands, making it structurally harder for smaller players to maintain or grow market share.

With online malls accounting for approximately 71% of distribution, platform advertising budgets and digital marketing sophistication largely determine visibility and sales conversion—areas where smaller companies like Daedong are at a pronounced disadvantage relative to well-capitalized incumbents.

Near-Zero KONEX Liquidity Severely Impairs Price Discovery

The reference-date trading value of just KRW 2,080—equivalent to a single share—indicates virtually no market activity is occurring.

Across the broader KONEX market, daily average trading volumes have trended consistently lower over the past three years (from KRW 1.94 billion to KRW 1.65 billion to KRW 1.43 billion), while delistings continue to outnumber new listings.

This near-total absence of liquidity impairs the price discovery function, severely narrows the investor base, and structurally limits the market's utility as a meaningful capital-raising platform for growth-stage companies.

Risk factors

Raw Material Price Risk

Ginseng raw material prices are subject to significant volatility driven by cultivated area, weather conditions, and harvest outcomes. Rising procurement costs would compound an already severely eroded profitability base, and smaller companies with lower purchasing leverage face disproportionate exposure to this risk.

The long-term trend of declining domestic ginseng farming households also poses a potential structural risk to raw material supply security over the medium term. In the absence of long-term supply agreements or hedging strategies, earnings volatility could be amplified further.

Macro and Consumer Sentiment Risk

The health functional food sector tends to shift rapidly toward value-driven consumption when macroeconomic conditions weaken; in 2025, the average per-consumer purchase amount already declined modestly despite rising purchase penetration rates.

Prolonged high inflation and sluggish domestic consumption could dampen gift-giving demand for red ginseng products around traditional Korean holidays, eroding a key seasonal revenue pillar for smaller producers like Daedong.

With limited revenue scale, the company has a comparatively narrow buffer to absorb demand shocks, resulting in above-average sensitivity to macroeconomic uncertainty.

Competitive and Regulatory Risk

Regulatory changes governing functional ingredient approvals by South Korea's Ministry of Food and Drug Safety can materially affect product development timelines and marketing claims for smaller companies with limited regulatory affairs resources.

Accelerating consumer and market share gains by alternative functional ingredients—particularly probiotics and single-vitamin supplements—could erode the competitive position of red ginseng within the health functional food category.

Additionally, tightening food and dietary supplement regulations in target export markets, most notably US FDA requirements, represent a potential implementation risk that could increase the cost and complexity of the company's overseas channel expansion strategy.

Overall view

Daedong Korea Ginseng possesses differentiated assets in specialized red ginseng manufacturing expertise and a nascent overseas distribution network.

However, as evidenced by the 53.2% collapse in operating profit and 81.4% decline in net profit in FY2024, restoring profitability is the company's most urgent structural priority.

The maturation and near-stagnation of the domestic health functional food market—combined with intensifying brand concentration toward large incumbents—creates a structurally challenging environment for smaller competitors, with no clear near-term catalyst to reverse these trends visible at present.

The near-total illiquidity of the KONEX listing remains a critical constraint, impairing price discovery and severely limiting investor accessibility.

On the constructive side, the global repositioning of red ginseng into anti-aging, blood glucose management, and brain health applications, alongside the potential to deepen existing export relationships, could serve as meaningful medium-to-long-term growth catalysts.

Translating these opportunities into tangible earnings improvement, however, requires concurrent progress on product upgrading, digital competitiveness, and cost optimization—outcomes unlikely to materialize in the near term.

A cautious observational stance appears most appropriate at this juncture, pending visible evidence of financial recovery and improved liquidity conditions.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 9 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.